- Home
- JANX vs EXTR Comparison
JANX vs EXTR Comparison
Compare JANX & EXTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- EXTR
- Stock Information
- Founded
- JANX 2017
- EXTR 1996
- Country
- JANX United States
- EXTR United States
- Employees
- JANX N/A
- EXTR N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- EXTR Telecommunications Equipment
- Sector
- JANX Health Care
- EXTR Telecommunications
- Exchange
- JANX Nasdaq
- EXTR Nasdaq
- Market Cap
- JANX 1.6B
- EXTR 1.8B
- IPO Year
- JANX 2021
- EXTR 1999
- Fundamental
- Price
- JANX $26.37
- EXTR $14.82
- Analyst Decision
- JANX Strong Buy
- EXTR Strong Buy
- Analyst Count
- JANX 7
- EXTR 7
- Target Price
- JANX $94.29
- EXTR $18.29
- AVG Volume (30 Days)
- JANX 974.6K
- EXTR 1.6M
- Earning Date
- JANX 05-20-2025
- EXTR 04-30-2025
- Dividend Yield
- JANX N/A
- EXTR N/A
- EPS Growth
- JANX N/A
- EXTR N/A
- EPS
- JANX N/A
- EXTR N/A
- Revenue
- JANX $10,588,000.00
- EXTR $1,089,717,000.00
- Revenue This Year
- JANX N/A
- EXTR $3.03
- Revenue Next Year
- JANX $250.58
- EXTR $8.34
- P/E Ratio
- JANX N/A
- EXTR N/A
- Revenue Growth
- JANX 30.99
- EXTR N/A
- 52 Week Low
- JANX $22.52
- EXTR $10.10
- 52 Week High
- JANX $71.71
- EXTR $19.24
- Technical
- Relative Strength Index (RSI)
- JANX 39.10
- EXTR 68.18
- Support Level
- JANX $31.34
- EXTR $13.64
- Resistance Level
- JANX $33.97
- EXTR $14.10
- Average True Range (ATR)
- JANX 1.94
- EXTR 0.51
- MACD
- JANX -0.52
- EXTR 0.37
- Stochastic Oscillator
- JANX 22.76
- EXTR 94.74
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.